Drug Search Results
More Filters [+]

Piclidenoson

Alternative Names: piclidenoson, cf101, cf-101, cf 101
Latest Update: 2024-09-24
Latest Update Note: News Article

Product Description

Piclidenoson is an orally bioavailable, adenosine A3 receptor (A3AR) agonist with potential anti-inflammatory activity. Upon administration, piclidenoson selectively targets, binds to and activates the cell surface-expressed A3AR, thereby activating transduction pathways in which A3AR plays a key role.

Mechanisms of Action: ADORA3 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ewopharma AG
Company Location:
Company CEO:
Additonal Commercial Interests: Can-Fite BioPharma

Clinical Description

Map of Global Clinical Trials for Piclidenoson

Countries in Clinic: Bosnia, Bulgaria, Canada, Croatia, Israel, Moldova, Poland, Romania, Serbia

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Psoriasis

Phase 2: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CF101-301PS

P3

Completed

Psoriasis

2022-04-28

CF101-241COVID-19

P2

Completed

COVID-19

2022-03-06

24%

2021-002009-85

P2

Completed

COVID-19

2022-01-06

CF101-301PS

P3

Completed

Psoriasis

2022-01-06

58%

Recent News Events